Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Recruiting Phase 2 Interventional

Assessment of Biomarker-Guided CNI Substitution In Kidney Transplantation

ClinicalTrials.gov ID: NCT05917522

Public ClinicalTrials.gov record NCT05917522. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 2, 2026, 12:11 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Assessment of Biomarker-Guided Calcineurin Inhibitor (CNI) Substitution In Kidney Transplantation (RTB-015)

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

800 adult first time kidney transplant recipients will be enrolled in the Observational Study and followed to evaluate their Human Leukocyte Antigen (HLA)-DR/DQ molecular mismatch (mMM) score as a risk-stratifying prognostic biomarker. Six months after transplant the study will identify those who meet the eligibility criteria for the Nested Randomized Control Trial (RCT). 300 eligible subjects will be randomized 2:1 to abatacept or Standard of care (SOC) in the randomization and followed for 18 months monitoring for safety and improvement in renal function, neurocognitive function, and a life participation patient reported outcome measure (PROM). The primary objective of the Observational Study is to test the validity of the HLA-DR/DQ mMM score as a prognostic biomarker for stratification of post-transplant alloimmune risk. Whereas the objective of the Nested RCT is to test whether a superior outcome in kidney function (primary endpoint), as well as secondary endpoints (neurocognitive function, and life participation PROM), will be achieved in patients who are transitioned from Tacrolimus (TAC) to abatacept, while maintaining efficacy (freedom from biopsy proven acute rejection).

Study identification

NCT ID
NCT05917522
Recruitment status
Recruiting
Study type
Interventional
Phase
Phase 2
Enrollment
800 participants

Conditions and interventions

Interventions

Biological · Procedure

Eligibility (public fields only)

Age range
18 Years to 70 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Dec 6, 2023
Primary completion
Jun 30, 2027
Completion
Jun 30, 2029
Last update posted
Mar 22, 2026

2023 – 2029

United States locations

U.S. sites
15
U.S. states
13
U.S. cities
14
Facility City State ZIP Site status
University of Alabama School of Medicine: Transplantation Birmingham Alabama 35233 Recruiting
Cedars Sinai Medical Center: Transplantation Los Angeles California 90048 Recruiting
Ronald Reagan UCLA Medical Center: Transplantation Los Angeles California 90095 Recruiting
Yale University, School of Medicine: Transplantation New Haven Connecticut 06519 Recruiting
Johns Hopkins Hospital:Transplantation Baltimore Maryland 21287 Recruiting
Massachusetts General Hospital: Transplantation Boston Massachusetts 02114 Recruiting
Mayo Clinic Rochester: Transplantation Rochester Minnesota 55905 Recruiting
Washington University School of Medicine in St. Louis St Louis Missouri 63110 Recruiting
University of Nebraska Medical Center: Transplantation Omaha Nebraska 68198 Recruiting
Duke University Medical Center: Transplantation Durham North Carolina 27710 Recruiting
Cleveland Clinic Foundation: Transplantation Cleveland Ohio 44195 Not yet recruiting
University of Pennsylvania Medical Center: Transplantation Philadelphia Pennsylvania 19104 Recruiting
University of Pittsburgh Medical Center: Transplantation Pittsburgh Pennsylvania 15213 Recruiting
University of Virginia Health System: Transplantation Charlottesville Virginia 22908 Recruiting
University of Wisconsin School of Medicine and Public Health: Transplantation Madison Wisconsin 53726 Not yet recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT05917522, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Mar 22, 2026 · Synced Sep 2, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT05917522 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →